Condition: Heart Failure · Sponsor: University of Rochester
This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.
This description comes directly from the study's public registry record.
Ilan Goldenberg, MD · 585-275-5391 · Ilan_Goldenberg@URMC.Rochester.edu
Misty Ra-Amari, BA · Misty_RaAmari@URMC.Rochester.edu
Always discuss trial participation with your own doctor first.
| Righospitalet | Copenhagen, Region H, Denmark | Recruiting |
| Centre Hospitalier De Pau | Pau, Gave de Pau, France | Recruiting |
| Hopital Trousseau Chru de Tours | Chambray-lès-Tours, Indre-et-Loire, France | Recruiting |
| Centre Hospitalier Universitaire de Bordeaux | Pessac, France | Recruiting |
| Unidad de Arritimias, Hospital Clínic Barcelona | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06543173